Skip to main content

My account

Boston Scientific accounts are for healthcare professionals only.

Create an account to access online training and education on EDUCARE, manage your customer profile, and connect with customer support and service teams.

My Boston Scientific account

Access your online applications and manage your customer profile.

Manage my Boston Scientific account

Quick Links

Contact a representative
Online education and training
Order products online
Reimbursement resources
Return a product
Customer support

Call customer care

1 (888) 272-1001

WaveWriter alpha scs system including: p16, r16, p32, r32 ipgs; leads; controller software on tablet; mySCS GO patient controller on phone; M8 and S8 adapters.

Proven. Profound. Different.

WaveWriter Alpha™ Spinal Cord Stimulator System

SCS therapy that succeeds where others fail and gets it right the first time.

Discover the difference

Profound. Proven. Different.

When you’ve done everything right but aren’t getting the results you want for your patient, try something DIFFERENT. Using the first and only FDA-approved MRI conditional adapters, connect other manufacturers’ leads to Boston Scientific’s innovative SCS therapy.

Profound pain relief with FAST™ Therapy 

Our exclusive SCS FAST Therapy (Fast-Acting Sub-perception Therapy) delivers PROFOUND paresthesia-free pain relief in minutes that lasts for years.1-5

Discover FAST Therapy
Illustration of spinal cord injury area.

Proven SCS outcomes

Advanced SCS therapy options backed by robust clinical evidence

The WaveWriter Alpha SCS System offers all of Boston Scientific’s advanced therapies to provide a personalized treatment approach for each patient.

4 Level 1 randomized controlled trials and 4 real-world studies support the design, efficacy, and efficiency of Boston Scientific’s therapies.6-14

View the unmatched clinical data
4 Level 1 RCTs, 4 Real-world studies.

Different technology and outcomes

First and only MRI conditional adapters in SCS

Give your patients another option if their Abbott or Medtronic SCS therapy is no longer effective by connecting to Boston Scientific.‡ With MRI conditional adapters, patients maintain full-body MRI access.*

Boston Scientific's SCS therapy enables 60% salvage rate for failed trials and implants.15,16

M8/S8 adapter.
Infinion pro leads within spine.

Infinion™ Pro Percutaneous Lead

Confident coverage now and in the future

The first and only 16 contact lead, spanning 3 vertebral levels with tight contact spacing, designed to address your patients' evolving pain.

Explore the Infinion Pro Lead
mySCS GO App on mobile phone, displaying Fast Autodose program.

mySCS™ GO Therapy Controller

The most comprehensive portfolio in SCS just got more personalized

The mySCS GO Therapy Controller is a discrete, easy-to-use remote control that makes adjusting SCS therapy settings simple, safe and secure.

And, to help build the future of data-driven insights, mySCS GO automatically uploads 200+ data points weekly to the cloud, allowing for future therapy advancements.

WaveWriter alpha scs system including: p16, r16, p32, r32 ipgs; leads; controller software on tablet; mySCS GO patient controller on phone; M8 and S8 adapters.

Comprehensive portfolio

WaveWriter Alpha™ SCS System

Full-body MRI conditional* portfolio of rechargeable and primary cell IPGs (16 and 32 contacts) with multi-lumen percutaneous leads and paddles.

Integrate the WaveWriter Alpha SCS System into your practice

Connect with us

Have a Boston Scientific representative contact you to learn more about the WaveWriter Alpha SCS System and our other pain management therapies.

Request a rep to try the WaveWriter Alpha SCS System

Subscribe for updates

Receive timely access to major announcements, opportunities to connect with your peers through educational events, and useful tools for you to help more patients.

Sign up

For a list of compatible mobile devices, visit www.myscsjourney.com/mySCSGO. The mySCS™ GO Therapy Controller Application is compatible with the WaveWriter Alpha Spinal Cord Stimulation System only.

*MRI Conditional under specified conditions

†Disclaimer: These outcomes reflect approximated data as determined in the referenced studies.

‡ Refer to the Precision M8 Adapter Directions for Use for indications, warnings and cautions. The Precision M8 Adapter is compatible with the following Medtronic lead and extension model numbers: 39286, 39565, 3778, 3878, 3777, 3877, 3776, 3876, 3874, 3873, 3875, 37081, 37083, 37082, 977A160, 977A175, 977A190, 977A260, 977A275, 977A290, 977D160, 977D260, 977C165, 977C265, 977C190, 977C290

Refer to the “Precision™ S8 Adapter Directions for Use” for indications, warnings and cautions. The Precision™ S8 Adapter is compatible with the following St Jude Lead, Adapter and Extension model numbers: 3283, 3268, 3269, 3280, 3244, 3262, 3263, 3245, 3264, 3265, 3208, 3210, 3288, 3289, 3214, 3219, 3228, 3183, 3186, 3189, 3191, 3086, 3286, 2283, 3341, 3342, 3343, 3346, 3382, 3383, 3386.

Sub-perception stimulation has been demonstrated to be safe and effective in patients who have been treated successfully with conventional, paresthesia-inducing stimulation for at least six months. Full stimulation parameter ranges and options for both paresthesia based and sub-perception therapy are available for clinician’s use throughout the patient’s experience and treatment with SCS.

Results from clinical studies are not predictive of results in other studies. Results in other studies may vary.

  1. Gage E., et al. Rapid Onset of Analgesia during Trial Period Utilizing Fast-Acting Sub-Perception Therapy SCS [Abstract] NANS 2023 Annual Meeting, Jan 12-15, 2023. (n=44)
  2. Anitescu M., et al. Utilizing SCS Designed to Engage Surround Inhibition Using Fast-Acting Sub-Perception Therapy (FAST): Prospective, Multicenter, Long-Term Outcomes [Abstract] NANS 2025 Annual Meeting, Jan 30-Feb 1, 2025. (n=20)
  3. Metzger C., et al. Two-year Outcomes Using Fast-Acting Sub-perception Therapy for Spinal Cord Stimulation: Results of a Real-World Multicenter Study in the United States. Expert Rev Med Devices. Published online January 2025. (n=50)
  4. Bayerl S, Paz-Solis J, Matis G, et al. Two-year outcomes using fast-acting, sub-perception therapy for spinal cord stimulation: a European, real-world, multicenter experience. JCM. 2024;13(22):6999. (n=52)
  5. Ferro R. et al. Streamlining Spinal Cord Stimulation Therapy via Personalized Automation of Programming [Abstract] NANS 2025 Annual Meeting, Jan 30-Feb 1, 2025. (n=23)
  6. Thomson SJ, Tavakkolizadeh M, Love-Jones S, et al. Effects of rate on analgesia in kilohertz frequency spinal cord stimulation; results of the PROCO randomized controlled trial. Neuromodulation. 2018;21(1):67-76. (n=20)
  7. Paz-Solis J. Thomson S, Jain R. Chen L, Huertas I, Doan Q. Exploration of high- and low-frequency options for subperception spinal cord stimulation using neural dosing parameter relationships: the HALO study. Neuromodulation, 2022;25(1):94-102. (n=30)
  8. North J, Loudermilk E, Lee A, et al. Outcomes of a multicenter, prospective, crossover, randomized controlled trial evaluating subperception spinal cord stimulation at ≤1.2 khz in previously implanted subjects. Neuromodulation. 2020:23(1):102-108. (n=140)
  9. Veizi E, Hayek SM, North J, et al. Spinal cord stimulation (SCS) with anatomically guided (3d) neural targeting shows superior chronic axial low back pain relief compared to traditional scs-lumina study. Pain Med. 2017;18(8):1534-1548. (n=169)
  10. Wallace MS, North JM, Phillips GM, et al. Combination therapy with simultaneous delivery of spinal cord stimulation modalities: COMBO randomized controlled trial. Pain Manag. 2023:13(3):171-184. (n=59)
  11. Metzger CS, Hammond MB, Pyles ST, et al. Pain relief outcomes using an SCS device capable of delivering combination therapy with advanced waveforms and field shapes, Expert Rev Med Devices. 2020;17(9):951-957. (n=84)
  12. Metzger C, et al. Long-Term Chronic Pain-Relief Outcomes Using an SCS System Capable of Combination Therapy (WaveWriter Outcomes Study] [Abstract]. Twenty-fifth Annual Meeting of the North American Neuromodulation Society, January 13-15th, 2022. (n=84)
  13. North J., et al. Evaluating SCS and Medical Management for Chronic Pain Without Prior Surgery: SOLIS RCT 24-Month Outcomes [Abstract], NANS 2025 Annual Meeting, Jan 30- Feb l, 2025. (n=77)
  14. Rauck R. et al. Real-World Outcomes Using Spinal Cord Stimulation for Treatment of Chronic Back Pain with No Prior Back Surgery [Abstract 88). Third joint Congress of the INS European Chapters, August 31-September 2nd, 2023, (n=48)
  15. Haider N, Ligham D, Quave B, et al. Spinal cord stimulation (SCS) trial outcomes after conversion to a multiple waveform SCS system. Neuromodulation. 2018:21(5):504-507. (n=16)
  16. Rigoard P. Billot M. Bougeard R, et al. Improved outcomes and therapy longevity after salvage using a novel spinal cord stimulation system for chronic pain: multicenter, observational, European case series. J Clin Med. 2024;13(4):1079. (n=43)

View Boston Scientific Spinal Cord Stimulator System Indications, Safety, and Warnings